HOME >> BIOLOGY >> NEWS
Fe-TAML(R) activators developed at Carnegie Mellon decontaminate anthrax simulant

NEW YORK-Carnegie Mellon University scientists today announced that one of their powerful, environmentally friendly catalysts called Fe-TAMLR activators has the potential to become an important cleanup tool for anthrax contamination.

The Fe-TAML activator used with hydrogen peroxide can substantially decontaminate a cultured, benign simulant of anthrax, they said. This anthrax simulant is commonly used in the laboratory testing of agents designed to eliminate its more deadly cousin, which is considered a significant biological warfare and terrorist threat.

The results of initial laboratory investigations are being presented by Carnegie Mellon graduate student Deboshri Banerjee on Wednesday, Sept. 10, in New York City at the 226th annual meeting of the American Chemical Society (paper 158, "Deactivation of bacterial spores using TAML-peroxide technology towards developing an efficient process for water disinfection," Industrial & Engineering Chemistry Division). The National Science Foundation funded this research.

"In our laboratory tests, Fe-TAMLs are highly promising in cleaning up an anthrax simulant, Bacillus atrophaeus," said Terry Collins, the Thomas Lord Professor of Chemistry at Carnegie Mellon and the chief researcher on the Fe-TAML project. "These results indicate the enormous potential of Fe-TAMLs to kill the lethal strain of anthrax and to eradicate other water-borne infectious microbes that account for significant death and disability worldwide."

A common simulant for anthrax testing, Bacillus atrophaeus is a species of spore closely related to Bacillus anthracis, the spore that causes debilitating, often fatal anthrax. According to the Center for Disease Control (CDC), anthrax is an agent with recognized bioterrorism potential. The CDC classifies it as a Category A agent, meaning that it poses the greatest possible threat to public health, that it may spread across a large area quickly and that its pr
'"/>

Contact: Lauren Ward
wardle@andrew.cmu.edu
412-268-7761
Carnegie Mellon University
10-Sep-2003


Page: 1 2 3

Related biology news :

1. Fe-TAML(R) activators developed at Carnegie Mellon remove recalcitrant sulfur from automotive fuels
2. Fe-TAML(R) activators developed at Carnegie Mellon break down toxic pesticides
3. Fe-TAML(R) activators developed at Carnegie Mellon help cleanup paper and wood pulp manufacturing
4. Fe-TAML(R) activators developed at Carnegie Mellon decolorize textile mill wastewater
5. Computer database being developed at Temple will allow for better inventory of chemicals
6. New software developed at Rensselaer predicts promising ingredients for new drugs
7. New imaging technique developed to identify breast cancer
8. Portable kidney dialysis machine developed
9. New method of identifying and isolating stem cells developed
10. Study calls for cheaper antitoxins for plant poisoning in less-developed countries
11. Drug developed for rare disease may help millions more as treatment for cancer, autoimmune diseases

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/31/2020)... ... 30, 2020 , ... BioFactura, Inc. today announced a $1 ... Science & Technology Office—Chemical and Biological Defense (JSTO-CBD) of the Department of Defense ... highly efficient mammalian cell culture-based bioprocess suitable to meet surge requirement needs for ...
(Date:7/10/2020)... ... July 08, 2020 , ... Overcoming ... Therapy Regulation, An FDAnews Webinar, Wednesday, July 22, 2020 • 1:30 p.m.-3:00 p.m. ... what is the most effective way to complete one? Will the study comply ...
(Date:7/1/2020)... ... July 01, 2020 , ... Catalent, a global leader ... Teva-Takeda Pharmaceuticals’ packaging facility in Minakuchi, located in the Shiga prefecture of Japan. ... in Kakegawa, the new 60,000-square-foot facility will provide customers with flexible clinical supply ...
Breaking Biology News(10 mins):
(Date:7/18/2020)... ... 2020 , ... dicentra , a leading Contract Research ... is pleased to announce that Charles Galea has joined its clinical trials division ... an accomplished and results-driven sales executive with over 10 years of expertise in ...
(Date:7/10/2020)... LEXINGTON, Mass. (PRWEB) , ... July 09, 2020 ... ... novel approaches to cell therapy, today announced the hiring of Allen R. Nissenson, ... executive team and oversee the clinical development of Sentien’s lead product, SBI-101. ...
(Date:7/1/2020)... ... 29, 2020 , ... The Interlocal Purchasing System (TIPS), a ... recently named BioFit Engineered Products an Awarded Vendor. Awarded Vendor status ... cafeteria tables, book trucks and carts at discounted pricing without the delay and ...
(Date:6/28/2020)... ... June 25, 2020 , ... ... photodynamic therapy for treating cancer, today announced the company has entered a license ... The agreement provides Lumeda globally exclusive rights to Roswell Park intellectual property ...
Breaking Biology Technology:
Cached News: